Continuous positive airway pressure

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

Sleep Apnea Symptoms Linked to Memory and Thinking Problems

Retrieved on: 
Monday, March 4, 2024

"Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."

Key Points: 
  • "Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."
  • Of those with symptoms, 357 people, or 33%, reported memory or thinking problems compared to 628 people, or 20% of people without sleep apnea symptoms.
  • After adjusting for other factors that could affect memory and thinking problems, such as age, race, gender and education, researchers found that people who reported sleep apnea symptoms were about 50% more likely to also report having memory or thinking problems compared to people who did not have sleep apnea symptoms.
  • Additional studies are needed following people's sleep apnea, memory and thinking symptoms over time.

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Retrieved on: 
Tuesday, February 6, 2024

In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.

Key Points: 
  • In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.
  • Vivos-trained providers currently treat failed HGNS cases using Vivos CARE oral medical devices and treatment plans.
  • Vivos believes most OSA patients seeking HGNS implants have high-moderate or severe OSA, leaving Vivos CARE oral medical devices as their only approved oral appliance therapy option.
  • We believe all of these factors create very significant revenue opportunities for us as we continue to spread the word about our product offerings.”

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Retrieved on: 
Wednesday, January 17, 2024

IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study.

Key Points: 
  • IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study.
  • The approval process involves review of the research protocol, informed consent procedures, recruitment materials, and participant risk versus benefit analysis.
  • The study is designed to facilitate a seamless transition between Phase 2 and Phase 3, reducing downtime and accelerating development timelines.
  • IRB approval of the protocol allows the U.S.-based sites to proceed with site-specific approval, which is a critical step in site activation.

Woburn Dentist Treats Sleeping Disorders Using Oral Appliance Therapy

Retrieved on: 
Thursday, January 4, 2024

WOBURN, Mass., Jan. 4, 2024 /PRNewswire/ -- Woburn Dentistry now offers a variety of treatment options for patients with snoring and sleep apnea disorders. Trained in dental sleep medicine and sedation, Dr. Jamie Chan offers an alternative to CPAP (continuous positive airway pressure) for patients with sleep apnea. For more information about the dental appliances the clinic offers, including custom sleep apnea appliances, please visit www.woburndentistryma.com/oral-appliance-therapy.

Key Points: 
  • Woburn Dentistry offers treatments for patients with sleep disorders and sleep apnea.
  • WOBURN, Mass., Jan. 4, 2024 /PRNewswire/ -- Woburn Dentistry now offers a variety of treatment options for patients with snoring and sleep apnea disorders.
  • Trained in dental sleep medicine and sedation, Dr. Jamie Chan offers an alternative to CPAP (continuous positive airway pressure) for patients with sleep apnea.
  • While CPAP is the most effective treatment for severe sleep apnea, oral appliance therapy is a simpler and easier FDA-approved solution for patients who cannot tolerate it.

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Tuesday, November 14, 2023

LITTLETON, Colo., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of third parties with non-FDA approved products in the sleep apnea treatment space has adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .
  • An online archive of the webcast will be available on the Company’s website for 30 days following the call.

Global Positive Airway Pressure Devices Pipeline Analysis Report 2023: Stages of Development, Segments, Region, Regulatory Path and Key Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 6, 2023

The "Positive Airway Pressure Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Positive Airway Pressure Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information about the Positive Airway Pressure Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Positive airway pressure is a method of respiratory ventilation used primarily in the treatment of sleep apnea.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date

CMS Sets Pricing with New HCPCS Codes for eXciteOSA Therapy, Expanding Access to Innovative Daytime Sleep Apnea Treatment

Retrieved on: 
Thursday, November 16, 2023

This milestone decision represents a significant step toward expanding access to innovative and effective treatment options for individuals with sleep apnea, especially those covered by Medicare.

Key Points: 
  • This milestone decision represents a significant step toward expanding access to innovative and effective treatment options for individuals with sleep apnea, especially those covered by Medicare.
  • The recent CMS HCPCS Level II coding decision became effective on October 1, 2023.
  • These decisions made by CMS demonstrate their recognition of the clinical value and potential impact of eXciteOSA therapy.
  • By providing a defined pricing structure, CMS is facilitating broader access to this innovative treatment, ensuring that eligible individuals covered by Medicare can benefit from its effects.

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Retrieved on: 
Wednesday, October 11, 2023

LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.

Key Points: 
  • LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.
  • “While Vivos believes in these results, it is important to apply the highest standards in medical research in the form of a prospective randomized controlled trial.
  • This will truly test Vivos’ treatment to the same standard as all other modalities.”
    “We are extremely excited to be starting this trial at Stanford Medicine, which has been in the works for some time” added R. Kirk Huntsman, Chairman and CEO of Vivos.
  • “I am confident that our technology will bear the scrutiny of a well-designed, prospective clinical trial.

Nyxoah Announces Partnership with ResMed in Germany

Retrieved on: 
Thursday, September 28, 2023

Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment.

Key Points: 
  • Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment.
  • The companies will collaborate on:
    “We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea.
  • Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.
  • The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.”